Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)
Portfolio Pulse from
Affimed's Acimtamig and AlloNK® combination has received RMAT designation from the FDA, based on promising early efficacy data in treating Relapsed/Refractory Hodgkin Lymphoma.
December 05, 2024 | 11:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Affimed's Acimtamig and AlloNK® combination therapy has been granted RMAT designation by the FDA, indicating strong early efficacy in treating Hodgkin Lymphoma.
The RMAT designation by the FDA is a significant regulatory milestone, suggesting that the therapy has shown substantial potential in early trials. This could lead to accelerated development and approval processes, positively impacting Affimed's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100